Allogene’s CAR-T could delay or prevent cancer recurrence
Key Points:
- Allogene Therapeutics said Monday that its off-the-shelf CAR-T treatment eliminated residual cancer cells in patients with B-cell lymphoma three times better than standard care — achieving the interim